Alpha-emitters for immuno-therapy: A review of recent developments from chemistry to clinics

Current Topics in Medicinal Chemistry

Volumn 12, Issue 23, 2012, Pages 2642-2654

  Huclier Markai, Sandrine ^a   Alliot, Cyrille ^b,c   Varmenot, Nicolas ^b,d   Cutler, Cathy S ^e   Barbet, Jacques ^b,c  

^a UNIVERSITÉ DE NANTES   (France)

^b GIP Arronax   (France)

^c INSERM   (France)

^d Centre Gauducheau Institut de Cancerologie de l'Ouest   (France)

^e UNIVERSITY OF MISSOURI   (United States)

Author keywords

212Pb, 212Bi, 213Bi, 211At, 223Ra, 225Ac

Indexed keywords

ACTINIUM 225; ASTATINE 211; BISMUTH 212; BISMUTH 213; CYTARABINE; LEAD 212; LINTUZUMAB; MISCELLANEOUS DRUGS AND AGENTS; NANOPARTICLE; RITUXIMAB; TRASTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ALPHA RADIATION; ALPHA RADIATION EMITTER; ANTIBODY LABELING; ARTICLE; CHEMISTRY; COMPLEX FORMATION; DNA DAMAGE; DOSIMETRY; GLIOMA; HUMAN; IMMUNOTHERAPY; LINEAR ENERGY TRANSFER; LIQUID LIQUID EXTRACTION; LYMPHOMA; MELANOMA; METASTASIS; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PURIFICATION; RADIOBIOLOGY;

ALPHA PARTICLES; ANTIBODIES; CHELATING AGENTS; CLINICAL TRIALS AS TOPIC; HALF-LIFE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOMETRY; RADIOPHARMACEUTICALS;

EID: 84874828305     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611212230002     Document Type: Article

References (128)

1. Regaud, C.; Lacassagne, A. La radiosensibilité cellulaire étudiée dans l'ensemble de ses manifestations. Radiophysiol. Radiother., 1927, 1, 95-116.
2. Britz-Cunningham, S.H.; Adelstein, S.J. Molecular targeting with radionuclides: state of the science. J. Nucl. Med., 2003, 44, 1945-1961.
3. Chérel, M.; Davodeau, F.; Kraeber-Bodere, F.; Chatal, J.F. Current Status and Perspectives in Alpha Radioimmunotherapy. Q. J. Nucl. Med. Mol. Imaging, 2006, 50(4), 322-329.
4. 90Y. Int. J. Radiat. Oncol. Biol. Phys., 1984, 10, 341-348.
5. 213Bi. Nucl. Med. Biol, 1998, 25, 241-246.
6. D.A. Alpha Particle Therapy for Cancer.Symposium on Radioisotopes in Mediicine: New Promise for the Treatment of Cancer. Seattle, WA, 1997.
7. Mulford, D.A.; Scheinberg, D.A.; Jurcic, J.G. The Promise of Targeted a-Particle Therapy. J. Nucl. Med, 2005, 46 (1), 199S-204S.
8. Couturier, O.; Supiot, S.; Degraef-Mougin, M.; Faivre-Chauvet, A.; Carlier, T.; Chatal, J.F.; Davodeau, F.; Cherel, M. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur. J. Nucl. Med. and Mol. Imag., 2005, 32(5), 601-614.
9. Supiot, S.; Thillays, F.; Rio, E.; Mahé, M.-A.; Barbet, F.-J.; Krae-ber-Bodéré, F.; Chérel, M. Alpha-radioimmunotherapy: a review of recent developments. Cancer/Radiothérapie 2007, 11, 252-259.
10. S., Generator-produces Alpha-emitters, Appl. Rad. Isot, 1998, 49, 345-349.
11. Elgqvist, J. The Magic Bullet: Moving the Concept Towards Reality - Part I, Cuur. Radiopharm. 2011, 4(3), 176.
12. Darrell R. Fisher Commercial Availability of Alpha-Emitting Radionuclides for Medicine Cuur. Radiopharm., 2008, 1(3), 127-134.
13. Elgqvist, J. The Magic Bullet: Moving the Concept Towards Reality - Part II. Curr. Radiopharm. 2011, 4(4), 281.
14. Tove Olafsen, Jorgen Elgqvist and Anna M. Wu. Protein Targeting Constructs in Alpha Therapy.Curr. Radiopharm., 2011, 4(3), 197-213.
15. Koch, L.; Apostolidis, C.; Janssens, W.; Molinet, R; Van Geel, J. Production of Ac-225 and application of the Bi-213 daughter in Cancer Therapy. Czech. J. Phys., 1999, 49, 817-822.
16. Sgouros, G.; Hobbs, R.F.; Song, H. Modelling and dosimetry for alpha-particle therapy. Curr. Radiopharm., 2011, 4(3), 261-265.
17. Sgouros, G.; Roeske, J.C.; McDevitt, M.R.; Palm, S.; Allen, B.J.; Fisher, D.R.; Brill, A.B.; Song1, H.; Howell, R.W.; Akabani, G. MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of a-Particle Emitters for Targeted Radionuclide Therapy. Journal of Nuclear Medicine Vol. 51 No. 2 311-328 (2010)
18. Chouin, N.; Bardies, M. Alpha-particle microdosimetry. Curr. Radiopharm., 2011, 4(3), 266-280.
19. B.J. Future Prospects for Targeted Alpha Therapy. Curr. Radiopharm, 2011, 4(4), 336-342.
20. Bardiès, M. Dosimetry and microdosimetry of targeted radiotherapy. Current Pharmaceutical Design, 2000, 6, 1469-1502.
21. Roeske, J.C. Small-scale dosimetry: challenges and future directions, Seminars in Nuclear Medicine, 2008.
22. Narbutt, J.; Bilewicz, A. Gamma emitting radiotracers Ra-224, Pb-212 and Bi-212 from natural thorium. Appl. Radiat. Isot., 1998,49, 89-91.
23. +203Pb nuclear reaction. Talanta, 1989, 36(4), 451-455
24. Biesuz, R.; Alberti, G.; Pesavento, M. Sorption of Lead(II) on Two Chelating Resins: From the Exchange Coefficient to the Intrinsic Complexation Constant. J. Solution Chem., 2008, 37, 527-541.
25. 212Bi generator using Indium-DTPA-tagged liposomes, Radiochimica acta, 2011, 99, 743-749.
26. 212Bi. Appl. Rad. Isot., 1994, 45, 1021-1025.
27. Mausner L.F., Mirzadeh S., Maher R., Vanchiere J.A., Srivastava S.C. Production of high specific activity 117mSn with the szilard-chalmers process, J. Label. Compd Radiopharm, 1989, 26, 177-178,
28. Horak E, Hartmann F, Garmestani K, Wu C, Brechbiel M, Gansow OA, Landolfi NF, Waldmann TA. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. J. Nucl. Med., 1997, 38, 1944-1950.
29. 203Pb labeled monoclonal antibodies. Inorg. Chim. Acta, 1995, 239, 43-51.
30. 212Pb-labeled monoclonal antibody in the treatment of murine erythroleukemia. Int. J. Radiat. Oncol. Biol. Phys., 1996, 34(3), 609-616.
31. Yao, Z.; Garmestani, K.; Wong, K.J.; Park, L.S.; Dadachova, E.; Yordanov, A.; Waldmann, T.A.; Eckelman, W.C.; Paik, C.H.; and Carrasquillo, J.A. Comparative Cellular Catabolism and Retention of Astatine, Bismuth and Lead-Radiolabeled Internalizing Monoclonal Antibody. J. Nucl. Med., 2001, 42(10), 1538-1544.
32. Brechbiel, M.W.; Gansow O.A. Synthesis of C-Functionalized trans-Cyclohexyldiethylnenetriaminepenta-acetic acid for Labeling of monoclonal antibodies with the bismuth-212 alpha-particle emitter. J. Chem. Soc. Perkin Trans., 1992, 1, 1173-1178.
33. 2-Radiochim Acta, 1993, 60, 1-10.
34. 212Bi. Radiochim. Acta, 2003, 91,109-113.
35. Glentworth, P.; Wright, C.L., Chemical effects of nuclear transformations of complexed metal atoms-I: The beta-decay of 144Ce and 143Ce complexed with polyaminopolycarboxylic acid chelating ligands. J. Inorg. Nucl. Chem., 1969, 31, 1263-1282.
36. Shiowaka T., Kido H., Omori T. Chemical Effects Associated with the p-Decay Process. V. Kinetic Studies of the Chemical Behavior of the 144Pr Formed by the Decay of the 144Ce(III)- Ethylenediaminetetraacetateand 144Ce(III)-trans-1,2- Diaminocyclohexane-N,N'-tetraacetate. Bull. Chem. Soc. Japan, 1970, 43, 2076-2079.
37. Asano, S.; Aida, T.; Inoue, S. J. Inorg. Nucl. Chem., 1978, 36, 2076.
38. Rosenow M.K., Zucchini G.L., Bridwell P.M., Stuart F.P., Friedman A.M. Properties of Liposomes Containing 212Pb. Int. J. Nucl. Med. Biol, 1983, 10(4), 189-193
39. Kozak RW, Goldman CK, Waldmann TA. Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy. Proc Natl Acad Sci U S A. 1986, 83(2), pp 474-478.
40. 213Bi-labeled antibody constructs for clinical use. J Nucl Med., 1999, 40, 1722-1727.
41. Finn RD, McDevitt MR, Scheinberg DA, et al. Refinements and improvements for Bi-213 production and use as a targeted therapeutic radiopharmaceutical. J Label Compd Radiopharm., 1997, 40, 293-299.
42. Ma D., McDevitt M.R., Finn R.D., Scheinberg D.A. Rapid preparation of short-lived alpha particle emitting radioimmunopharma-ceuticals. Applied Rad Isot, 2001a, 55, 463-470.
43. Ma D., McDevitt M.R., Finn R.D., Scheinberg D.A. Breakthrough of 225Ac and its radionuclide daughters from an 225Ac/213Bi generator: development of new methods, quantitative characterization, and implications for clinical use. Applied Rad Isot, 2001b, 55, 667-678.
44. Briand, G.G.; Burford, N. Coordination Complexes of Bismuth(III) involving Organic Ligands with Pnictogen and Chalcogen Donors, Adv. Inorg. Chem, 2000, 50, 285-357.
45. Stavila V, Davidovich R, Gulea A, Whitmire K. Bismuth(III) complexes with aminopolycarboxylate and polyaminopolycarboxylate ligands: Chemistry and structure. Coord. Chem. Rev., 2006, 250, 2782-2810.
46. Hassfjell S, Brechbiel MW. Targeted a-therapy. Chem. Rev., 2001, 101, 2019-2023.
47. Yang, N.; Sun, H.Z. Biocoordination chemistry of bismuth: Recent advances. Coord. Chem. Rev., 2007, 251, 2354-2366.
48. Abbas, R.S.M.; Li, Y.; Song, E.Y.; Qu, C.F.; Raja, C; Morgenstern, A.; Apostolidis, C; Allen, B.J. Preclinical studies of bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model. Cancer Biol. Ther., 2006, 5, 386-393.
49. McDevitt MR, Nikula TN, Finn RD, Curcio MJ, Gansow OA, Geerlings MW Sr, Larson SM, Scheinberg DA. Bismuth labeled antibodies for therapy of leukemias, lymphomas, and carcinomas: preclinical studies. Tumor Target, 2, 182, 1996
50. Jurcic JG, DeBlasio T, Dumont L, Yao TJ, Scheinberg DA. 38. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res. 2000;6(2):372-380
51. Mulford, D.A.; Jurcic, J.G. Antibody-based treatment of acute myeloid leukaemia. Expert Opin Biol Ther., 2004 Jan;4(1):95-105
52. Nikula, TK; Curcio, MJ; Brechbiel, MW; Gansow, O.A.; Finn, RD; Scheinberg, DA. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity, and chemistry. J Nucl Med. 1999, 40, 166-176.
53. Joseph G. Jurcic, Steven M. Larson, George Sgouros, Michael R. McDevitt, Ronald D. Finn, Chaitanya R. Divgi, Åse M. Ballangrud, Klaus A. Hamacher, Dangshe Ma, John L. Humm, Martin W. Brechbiel, Roger Molinet and David A. Scheinberg. Targeted a particle immunotherapy for myeloid leukemia, Blood, 2002, 100, 1233-1239.
54. Qu C.F., Song Y.J., Rizvi S.M.A., Li Y., Smith R., Perkins A.C., Morgenstern A., Brechbiel M., Allen B.J. In Vivo and in Vitro Inhibition of Pancreatic Cancer Growth by Targeted Alpha Therapy Using 213Bi-CHX.A-C595. Cancer Biol. Ther., 2005, 4, 848-853.
55. Lindegren, S. and Frost, S.H.L. Pretargeted Radioimmonutherapy with a-particle emitting radionuclides. Curr. Radiopharm., 2011 4(3), 248-260.
56. Ruegg, C. L.; Anderson-berg, W. T.; Brechbiel, M. W.; Mirzadeh, S.; Gansow, O. A. Improved in vivo stability and tumor targeting of bismuth labeled antibody. Cancer Res., 1990 50, 4221-4226.
57. 212Bi) Therapy. Cancer Res., 1993, 53, 5683-5689.
58. 212Bi-labeled Antibody. Cancer Res., 1990, 50, 985-988.
59. Yao, Z.; Zhang, M.; Garmestani, K.; Axworthy, DB.; Mallett, RW.; Fritzberg, AR.; Theodore, LJ.; Plascjak, PS.; Eckelman, WC; Waldmann, TA; Pastan, I.; Paik, CH.; Brechbiel, MW.; Carras-quillo, JA. Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N,N'-tetraacetic acid-biotin. Clin Cancer Res. 2004, 10(9), 3137-3146.
60. Norenberg JP, Krenning BJ, Konigs IG, Kusewitt DF, Nayak TK, Anderson TA, deJong M, Garmestani K, Brechbiel MW, Kvols LK. 213Bi-DOTATOC Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors in a Pre-Clinical Animal Model. Clin. Cancer Res. 2006, 12(3), 897-903.
61. 177Lu in chemoresis-tant human pancreatic adenocarcinoma cells. Nucl. Med. Biol. 2007; 34(2):185-193.
62. Park, S.L., Shenoi, J.; Pagel, J.M.; Hamlin, D.K.; Wilbur, D.S.; Orgun, N.; Fisher, D.R.; Gopal, A.K.; Green, D.J.; Press, O.W. Conventional and pretargeted radioimmunotherapy using bismuth 213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Bolld, 2010, 116(20), 4231-4239.
63. Sofou S, Thomas J, Lin HY, McDevitt M, Scheinberg D, Sgouros G. Enhanced Retention of the a-Particle-Emitting Daughters of Ac-tinium-225 by Liposome Carriers. J. Nucl. Med., 2004, 45(2), 253-260.
64. Sgouros, G. Alpha-particles for targeted therapy. Adv. Drug Deliv. Rev., 2008, 60, 1402-1406.
65. D.A. Mulford, N. Pandit-Taskar, M.R. McDevitt, R.D. Finn, M.A. Weiss, C. Apostolidis, et al., Sequential therapy with cyta-rabine and bismuth-213 (Bi-213)-labeled-HuM195 (anti-CD33) for acute myeloid leukemia (AML). Blood, 2004, 104(11), 496A.
66. S. Heeger, G. Moldenhauer, G. Egerer, H. Wesch, S. Martin, T. Nikula, et al., alpharadioimmunotherapy of B-lineage non-Hodgkin's lymphoma using 213Bi-labelled anti-CD19-and anti-CD20-CHX-A -DTPA conjugates. Am. Chem. Soc, 2003, U261.
67. S. Kneifel, D. Cordier, S. Good, M.C.S. Ionescu, A. Ghaffari, S. Hofer, et al., Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10- tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance P. Clin. Cancer Res., 2006, 12 (12), 3843-3850.
68. B.J. Allen, C. Raja, S. Rizvi, Y. Li, W. Tsui, P. Graham, et al., Intralesional targeted alpha therapy for metastatic melanoma, Cancer Biol. Ther., 2005, 4 (12), 1318-1324.
69. Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, Heaney ML, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res., 2010, 16(21), 5303-5311.
70. th Alpha-Immunotherapy Symposium, Dusseldorf, Germany, June 28-29, 2004.
71. Allen, B.J.; Raja, C; Rizvi, S.; Li, Y.; Tsui, W.; Graham, P.; Thompson, J.F.; Reisfeld, R.A.; Kearsley, J.; Morgenstern, A.; Apostolidis, C. Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol. Ther., 2005, 4(12), 1318-1324.
72. Raja, C; Graham, P.; Abbas Rizvi, S.M.; Song, E.; Goldsmith, H.; Thompson, J.; Bosserhorff, A.; Morgenstern, A.; Apostolidis, C; Kearlsey, J.; Reisfeld, R.A.; Allen, B.J. Interim analysis of toxicity and response in Phase I trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol. Ther. 2007, 6(6), 846-852
73. Allen BJ, Singla AA, Rizvi SM, Graham P, Bruchertseifer F, Apostolidis C, Morgenstern A. Analysis of patient survival in a Phase I trial of systemic targeted a-therapy for metastatic melanoma. Immunotherapy. 2011, 3(9): 1041-50.
74. Cordier D, Forrer F, Bruchertseifer F, Morgenstern A, Apostolidis C, Good S, Müller-Brand J, Mäcke H, Reubi JC, Merlo A. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial. Eur J Nucl Med Mol Imaging. 2010 37(7): 1335-1344.
75. 213Bi. Curr. Radiopharm., 2011, 4, 295-305.
76. Zalutsky and Pruzynsky, Astatine-211: production and availability. Curr. Radiopharm., 2011, 4(3), 177-185.
77. Groppi F, Bonardi ML, Birattari C, Menapace E, Abbas K, Holzwarth U, Alfarano A, Morzenti S, Zona C, Alfassi ZB. Optimisation study of alpha-cyclotron production of At-211/Po-211g for high-LET metabolic radiotherapy purposes. Appl Radiat Isot. 2005, 63(5-6):621-631.
78. Svábová L, Lebeda A. In vitro selection for improved plant resistance to toxin-producing pathogens. J Phytopathol, 2005, 153, 52-64.
79. Lahiri, S.; Roy, K.; Sen, S. Complexation study on no-carrier-added astatine with insulin: A candidate radiopharmaceutical. Appl. Rad. Isot., 2008, 66, 1901-1904.
80. Roy, K.; Lahiri, S. Production and separation of Astatine Radionuclides: Some new addition to Astatine Chemistry. Appl. Rad. Isot, 2008, 66, 571-576
81. Alliot, C.; Chérel, M.; Barbet, J.; Sauvage, T.; Montavon, G. Extraction of astatine-211 in diisopropylether (DIPE). Radiochim. Acta, 2009, 97, 161-165.
82. Champion, J.; Alliot, C; Renault, E.; Mokili, B.M.; Chérel, M.; Galland, N.; Montavon, G. Astatine Standard Redox Potentials and Speciation in Acidic Medium. J. Phys. Chem. A 2010, 114, 576-582.
83. Champion, J.; Seydou, M.; Sabatié-Gogova, A.; Renault, E.; Montavon, G.; Galland, N. Assessment of an effective quasirelativistic methodology designed to study astatine chemistry in aqueous solution. Physical Chemistry Chemical Physics 2011, 13, 14984-14992.
84. Pruszyhski, M.; Bilewicz, A.; Zalutsky, M.R. Preparation of Rh[16aneS4-diol]211 At and Ir[16aneS4-diol]211 At Complexes as Potential Precursors for Astatine Radiopharmaceuticals. Part I: Synthesis. Bioconjug Chem. 2008, 19(4), 958-965.
85. Wilbur S.D. Chemical and Radiochemical Considerations in Radiolabeling with a-Emitting Radionuclides. Curr. Radiopharm. 2011, 4(3), 214-247
86. Bloomer WD, McLaughlin WH, Neirinckx RD, et al. Astatine-211-tellurium radiocolloid cures experimental malignant ascites. Science, 1981, 212, 340-341.
87. Brown I, Carpenter RN, Mitchell JS. The development of A [211At]-astatinated endoradiotherapeutic drug: part I. Localization by alpha-particle autoradiography in a murine tumor model. Int J Radiat Oncol Biol Phys., 1992, 23:563-572.
88. Brown I, Mitchell JS. The development of a [211At]-astatinated endoradiotherapeutic drug: part II. Therapeutic results for transplanted adenocarcinoma of the rectum in mice and associated studies. Int J Radiat Oncol Biol Phys 1994, 29, 115-124.
89. Link EM. Targeting melanoma with 211At/131I-methylene blue: preclinical and clinical experience. Hybridoma, 1999, 18, 77-82.
90. Vaidyanathan G, Zalutsky MR. 1-(m-[211At]astatobenzyl) gua-nidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation. Bioconjug Chem., 1992, 3, 499-503.
91. Vaidyanathan G, Larsen RH, Zalutsky MR. 5-[211At]astato-2 '-deoxyuridine, an alpha particle-emitting endoradiotherapeutic agent undergoing DNA incorporation. Cancer Res., 1996, 56, 1204-1209.
92. Foulon CF, Alston KL, Zalutsky MR. Astatine-211-labeled biotin conjugates resistant to biotinidase for use in pretargeted radioimmunotherapy. Nucl Med Biol 1998, 25, 81-88.
93. Murud KM, Larsen RH, Bruland OS, et al. Influence of pretreat-ment with 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APB) on organ uptake of 211At and 125I-labeled amidobisphos-phonates in mice. Nucl Med Biol., 1999, 26, 791-794.
94. Murud KM, Larsen RH, Hoff P, et al. Synthesis, purification, and in vitro stability of 211At- and 125I-labeled amidobisphosphonates. Nucl Med Biol 1999, 26, 397-403.
95. Larsen RH, Akabani G, Welsh P,. The cytotoxicity and microdo-simetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro. Radiat Res., 1998, 149, 155-162.
96. Zalutsky MR, Narula AS. Astatination of proteins using an N-succinimidyl tri-n-butylstannyl benzoate intermediate. Int J Radiat Appl Instrum A, 1988, 39, 227-232.
97. Zalutsky MR, Garg PK, Friedman HS, et al. Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particleemitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. Proc Natl Acad Sci U S A 1989, 86, 7149-7153.
98. Rosenkranz AA, Vaidyanathan G, Pozzi OR, Lunin VG, Zalutsky MR, Sobolev AS. Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to alpha-particle emitting 211 At. Int J Radiat Oncol Biol Phys. 2008, 72(1), 193-200.
99. Walicka MA, Vaidyanathan G, Zalutsky MR, et al. Survival and DNA damage in Chinese hamster V79 cells exposed to alpha particles emitted by DNA-incorporated astatine-211. Radiat Res 1998, 150, 263-268.
100. Strickland DK, Vaidyanathan G, Zalutsky MR. Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells. Cancer Res., 1994, 54, 5414-5419.
101. 211At labeled effector molecules. Synthesis and preclinical evaluation for pretargeted alpha-radioimmunotherapy. University of Gothenburg (Sweden), 2012, pp63.
102. Foulon, C.F.; Aston, K.L.; Zalutsky, M.R. Synthesis and Preliminary biological evaluation of (3-iodobenzoyl)norbiotinamide: two radioiodinated biotin conjugates with improved stability. Biocon-jug. Chem. 1997, 8(2), 179-186.
103. Vaidyanathan, G.; Zalutsky, M.R. Applications of 211At and 223Ra in Targeted Alpha-Particle Radiotherapy. Curr. Radio-pharm, 2011, 4(4), 283-294.
104. Reardon, D.A.; Zalutsky, M.R.; Bigner, D.D. Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Review of Anticancer Therapy, 2007, 7(5), 675-687.
105. Zalutsky, M.R.; Reardon, D.A.; Akabani, G.; Coleman, R.E.; Friedman, A.H.; Friedman, H.S.; McLenon, R.E.; Wong, T.Z.; Bigner, D.D. Clinical experience with a-emitting astatine-211 treatment of recurrent brain tumor patient with 211At-labeled chi-meric 81C6 antitenascin monoclonal antibody. J. Nucl. Med., 2008, 49, 30-38.
106. 211At-MX35 F(ab')2 - phase I study. J. Nucl. Med., 2009, 50, 1153-1160.
107. McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, Scheinberg DA. Radioimmunotherapy with alpha-emitting nu-clides. Eur J Nucl Med 1998, 25, 1341-1351.
108. Baetsle L.H., Fourth Int. Conf. on Peaceful Uses of Atomic Energy, Geneva, Paper A/CONF.49/P/287, Vol. 7, pp. 191-203. (1972)
109. Geerlings, M. W. Radionuclides for radioimmunotherapy: criteria for selection. Int. J. Biol. Markers, 1993, 8, 180-186.
110. McDevitt, M.R.; Ma, D.; Lai, L.T.; Simon, J.; Borchardt, P.; Frank, R.K., Wu, K.; Pellegrini, V.; Curcio, M.J.; Miederer, M.; Bander, N.H.; Scheinberg, D.A. Tumor Therapy with Targeted Atomic Nanogenerators. Science, 2001, 294, 1537-1540.
111. Miederer, M.; Scheinberg, D.A.; McDevitt, M.R. Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. Advanced Drug Delivery Reviews, 2008; 60(12), 1371-1382.
112. 225Ac radioimmunotherapy applications. Bioconj Chem, 2000, 11, 510-519.
113. 225Ac-radiopharmaceuticals. Appl Rad Isot, 2002, 57, 841-847.
114. Henriksen, G.; Schoultz, B.W.; Michaelsen, T.E.; Bruland, Ø.S.; Larsen, R.H. Sterically stabilized liposomes as a carrier for a-emitting radium and actinium radionuclides. Nucl. Med. Biol, 2004, 31, 441-449.
115. Sofou, S., Kappel, B. J., Jaggi, J. S., McDevitt, M. R., Scheinberg, D. A., Sgouros, G. Bioconj. Chem., 2007, 18, 2061-2067.
116. Woodward, J., Kennel, S.J., Stuckey, A., Osborne, D., Wall, J., Rondinone, A.J., Standaert, R.H., Mirzadeh, S. LaPO4 Nanoparticles Doped with Actinium-225 that partially Sequester Daughter Radionuclides. Biononjugate Chem. 2011, 22, 766-776.
117. McLaughlin, M., Woodward J., Broderick, M., Standaert, R., Rondinone, A., Robertson, D.R., Mirzadeh, S., Kennel, S.J. (2011) Synthesis and Characterization of a Novel Gold Coated LaGdPO4 Nanoparticles ContainingActinium-225. 7th Symposium on Targeted Alpha Therapy, Berlin, Germany July 17-19, 2011.
118. David A. Scheinberg; Michael R. Mcdevitt. Actinium-225 in targeted Alpha-particle therapeutic applications. Current Radiopharmaceuticals 2011; 4(4):306-320.
119. Deal, K.A.; Davis, I.A.; Mirzadeh, S.; Kennel, S.J.; Brechbiel, M.W. Improved in vivo stability of actinium-225 macrocyclics complexes. J. Nucl. Med, 1999, 42, 2988-2992.
120. 225Ac for vascular targeted radioimmunotherapy of lungs tumors. Cancer Biother. Radiopharm., 2000, 15, 235-244.
121. Escorcia, F.E.; Henke, E.; McDevitt, M.R.; Villa, C.H.; Smith-Jones, P.; Blasberg, R.G.; Benezra, R.; Scheinberg, D.A. Selective killing of tumor neo-vascularture paradoxically improves chemotherapy delivery to tumors. Cancer Res. 2010, 70(22), 9277-9286.
122. Nolan, D.J.; Ciarrocchi, A.; Mellick, A.S.; Jaggi, J.S.; Bambino, K.; Gupta, S.; Heikamp, E.; McDevitt, M.R.; Scheinberg, D.A.; Benezra, R.; Mittal, V. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes & Dev., 2007, 21, 1546-1558.
123. 90Y. Cancer Res., 2009, 69(23), 8941-8948.
124. Miederer, M.; Henriksen, G.; Alke, A.; Mossbrgger, I.; Quintilla-Martinez, L.; Senekowitsch-Schmidtke, R.; Essler, M. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. Clin. Cancer Res., 2008, 14(11), 3555-3561.
125. Nilson, S.; Larsen, R.H.; Fossa, S.D.; Balteskard, L.; Borch, K.W.; Westlin, J.E.; Salberg, G.; Bruland, O.S. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin. Cancer Res. 2005, 11, 4451-4459.
126. Henriksen, G.; Hoff, P.; Larsen, R.H. Evaluation of potential chelating agents for radium. Appl. Rad. Isot, 2002, 56, 667-671
127. Dahle, J.; Borrebæk, J.; Jonasdottir, T.J.; Hjelmerud, A.K.; Mel-hus, K.B.; Bruland, O.S.; Press, O.W.; Larsen, R.H. Targeted cancer therapy with a novel low-dose rate a-emitting radioimmunoconju-gate. Blood, 2007 110: 2049-2056.
128. Larsen RH, Borrebaek J, Dahle J, Melhus KB, Krogh C, Valan MH, Bruland OS Preparation of TH227-labeled radioimmunocon-jugates, assessment of serum stability and antigen binding ability. Cancer Biother Radiopharm, 2007, 22 (3), 431-437.